Opus Genetics (IRD) Tax Provisions (2022 - 2023)
Opus Genetics (IRD) reported Tax Provisions of -$2000.0 for Q4 2023, down 100.63% year-over-year from $315000.0 in Q4 2022, and down 114.29% on a QoQ basis from $14000.0 in Q3 2023.
Opus Genetics (IRD) has 2 years of Tax Provisions data on file, last reported at -$2000.0 in Q4 2023.
- Quarterly Tax Provisions fell 100.63% year-over-year to -$2000.0 in Q4 2023, while the trailing twelve-month figure through Sep 2024 was -$2000.0 (down 100.61% YoY) and the FY2023 annual result came in at $12000.0, down 96.19% from the prior year.
- Tax Provisions retreated to -$2000.0 in Q4 2023 per IRD's latest filing, from $14000.0 in the prior quarter.
- Across five years, Tax Provisions topped out at $315000.0 in Q4 2022 and bottomed at -$2000.0 in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | -11.20 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -859,000.00 |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 221.50 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 216,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 104.00 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 15.66 Mn |
| 10 | Opus Genetics | 357.99 Mn | 298.03 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -2,000.00 |
| Sep 30, 2023 | 14,000.00 |
| Dec 31, 2022 | 315,000.00 |